0

Rabies - A Pipeline Analysis Report

  • Published: Jun 2018
  • Pages: 95
  • SKU: IRTNTR22809
Technavio

The 2022-2026 version of this report is just being published. Buy it now and get up to $1000 worth of free customization!

Get me the latest version! (includes COVID-19 impact)
Safe and Secure SSL Encrypted
  • 2500.00
  • USD

This pipeline analysis report provides detailed insights into the clinical trials landscape of the drug development for rabies including molecules at pre-clinical and discovery stage. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as therapy, route of administration, by territory, therapeutic modality, and target.

Overview of the drug development pipeline for rabies  

Rabies is a viral disease that results in acute irritation of the brain in humans and other animals. This disease is spread from humans to animals such as dogs, cats, and cows. The saliva from an infected animal results in spreading rabies on contact with a human body part. Infected individuals offer symptoms such as incubation, prodrome, acute neurologic pain, and coma. These individuals are offered therapeutic treatments such as rabies immune globulin or series of rabies vaccine. In the last decade, US witnessed only 8 cases of human rabies in the US due to the extensive dog rabies vaccination programs conducted that stopped the natural spread of rabies among domestic dogs. With the increasing incidences of diseased mammals that are unvaccinated and infected due to contaminated wildlife, Technavio’s market research analysts have forecasted the extensive investment and drug development for suitable therapeutics for rabies in the forthcoming years.  

According to this pipeline analysis report, most of the drug development molecules in the pipeline are under the pre-clinical drug development stage followed by pre-clinical stage. Our market research analysts have also identified that similar amount of drug molecules are under the phase III and phase II drug development stage. The pipeline landscape in the pipeline analysis report also mentions the percentage of drug development molecules that are in the phase I, phase I/II, and phase II/III stage. 

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug development molecules for the treatment of rabies. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are:

  •  PROSETTA BIOSCIENCES
  • SYNERMORE BIOLOGIC
  • VBI VACCINE

Therapeutic assessment of the drug development pipeline for rabies by route of administration

  • Intradermal
  • Intradermal/intramuscular
  • Intramuscular

In the intramuscular route of administration (ROA), drug substances are administered within a muscle. It has been observed that the majority of therapeutics for rabies are being developed for intramuscular administration.

Therapeutic assessment of the drug development pipeline for rabies by therapies employed

  • Monotherapy
  • Combination

According to this pipeline analysis report, majority of the therapies employed are being developed in the form of monotherapy. In the monotherapy employed in this pipeline, a single drug is used to treat a particular disorder.

Technavio also offers customization on reports based on specific client requirement.

 

Read More Read Less

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION

PART 05: MAJOR REGULATORY AUTHORITIES

  • US
  • Europe
  • China

PART 06: PIPELINE LANDSCAPE

PART 07: COMPARATIVE ANALYSIS

  • Discovery stage molecules
  • Pre-clinical stage molecules
  • Inactive and discontinued molecules

PART 08: INDICATION ANALYSIS

PART 09: THERAPEUTIC ASSESSMENT (THERAPY BASED)

PART 10: THERAPEUTIC ASSESSMENT (ROA BASED)

PART 11: THERAPEUTIC ASSESSMENT BY TARGET

PART 12: KEY COMPANIES

  • Active companies: Category and parameters

PART 13: APPENDIX

  • List of abbreviations

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

TechnavioINFORMATION SOURCES

Primary sources

  • Manufacturers and suppliers
  • Channel partners
  • Industry experts
  • Strategic decision makers

Secondary sources

  • Industry journals and periodicals
  • Government data
  • Financial reports of key industry players
  • Historical data
  • Press releases
Technavio

TechnavioDATA ANALYSIS

Data Synthesis

  • Collation of data
  • Estimation of key figures
  • Analysis of derived insights

Data Validation

  • Triangulation with data models
  • Reference against proprietary databases
  • Corroboration with industry experts
Technavio

TechnavioREPORT WRITING

Qualitative

  • Market drivers
  • Market challenges
  • Market trends
  • Five forces analysis

Quantitative

  • Market size and forecast
  • Market segmentation
  • Geographical insights
  • Competitive landscape
Interested in this report?
Get your FREE sample now!
Safe and Secure SSL Encrypted
Technavio

Single User:

2500 USD

Technavio Get the report (PDF) sent to your email within minutes.

Subscribe & Save

Get lifetime access to our
Technavio Insights

Want to customize this report?

This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

We offer $1000 worth of FREE customization at the time of purchase
Technavio
Enquire Before Buying
  1. Home
  2. Health Care
  3. Published Report
17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>